Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cheap blood tests may flag hidden memory risk after stroke

NCT ID NCT07837466

NEW Diagnosis Sponsor: Assiut University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 23, 2026 · Last updated Sep 23, 2026

Summary

Researchers at Assiut University are studying whether common blood markers of inflammation can predict early cognitive impairment after a basal ganglia stroke. The study follows 100 adults aged 18 to 59 who are admitted within 72 hours of a first ischemic or bleeding stroke. Participants receive standard stroke severity scoring, brain imaging, and blood tests measuring ratios such as neutrophil-to-lymphocyte and C-reactive protein-to-lymphocyte. Three months later, they take a validated Arabic cognitive test to see whether the early blood markers matched later thinking and memory problems.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If the markers hold up, doctors could flag stroke patients at high risk of memory and thinking problems using cheap blood tests already done in hospital, then refer them early for cognitive rehabilitation.
What could go wrong
This is a small observational study of 100 people at one center, so it can only show a link, not prove cause. The markers may not predict cognitive decline reliably, and results in this age group may not apply to older stroke patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients aged 18 to 59 years presenting with a confirmed first-ever acute stroke (ischemic or primary intracerebral hemorrhage) with basal ganglionic involvement, admitted to the Stroke Unit of the Department of Neurology at Assiut University Hospitals within 72 hours of symptom onset.

Ages

18 to 59 years

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age between 18 and 59 years. * First-ever acute stroke (ischemic or primary intracerebral hemorrhage) confirmed by brain CT or MRI, with documented basal ganglionic involvement. * Hospital admission within 72 hours of symptom onset. * Written informed consent provided by the patient or their legally authorized representative. Exclusion Criteria: * Pre-existing cognitive impairment or dementia (e.g., Alzheimer's disease, vascular dementia). * Severe neurological or sensory deficits precluding cognitive assessment, including severe aphasia, altered level of consciousness, or significant visual or hearing impairment. * Severe organ dysfunction, including severe cardiac, hepatic, or renal insufficiency. * Medical conditions confounding systemic inflammatory markers, including active systemic infection, autoimmune disease, or recent major surgery/trauma. * Current or recent treatment with immunosuppressive drugs, systemic corticosteroids, or high-dose antibiotics.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Basal ganglia stroke are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

basal ganglia cerebrovascular disorder intracerebral hemorrhage ischemic stroke stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Basal ganglia stroke Intracerebral hemorrhage Ischemic stroke Post-stroke cognitive impairment Stroke

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.